- Appropriate patients may be switched directly from immediate-release ropinirole to REQUIP XL 1,2
- The initial switching dose of REQUIP XL should most closely match the total daily dose of immediate-release ropinirole 1,2
- Dosage may then be adjusted based on therapeutic response and tolerability 4
- In clinical trials, it was recommended that patients take REQUIP XL in the morning. 1,2
Provide new patients with a simple titration schedule
* Titration schedules for immediate-release ropinirole and REQUIP XL are only recommendations based on clinical observance. Dosage for patients should be titrated based on physician assessment of therapeutic response and tolerability.
- Patients should be assessed for therapeutic response and tolerability at a minimal interval of 1 week or longer after each dose increment
- Caution should be exercised during dose titration because too rapid a rate of titration may lead to dose selection that may not provide additional benefit but may increase the risk of adverse reactions
- Safety and effectiveness of REQUIP XL at doses greater than 24 mg/day have not been established
- Patients should be advised to swallow REQUIP XL whole and not to chew, crush, or divide the tablet.
NEXT:
Frequently Asked Questions about REQUIP XL
Important Safety Information
REQUIP XL has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Increase in blood pressure and changes in heart rate may occur. Hallucinations may occur at any time during treatment. Impulse control symptoms, including pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole. REQUIP XL may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesia.
Complete Prescribing Information for REQUIP XL
REQUIP XL has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Increase in blood pressure and changes in heart rate may occur. Hallucinations may occur at any time during treatment. Impulse control symptoms, including pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole. REQUIP XL may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesia.
Complete Prescribing Information for REQUIP XL